ENDRA Life Sciences reported Q3 2024 financial results and provided a business update. The company accelerated enrollment in its global multisite pilot study, with nearly 40 subjects enrolled or being scanned in the past two months. ENDRA also developed new AI-based data analysis features for its TAEUS platform and activated a system at LMU University Hospital in Germany for a post-market study.Operating expenses decreased 52% YoY to $1.5 million in Q3 2024. Net loss was $2.4 million, including a $911,000 non-cash charge related to warrants. Cash and equivalents stood at $4.7 million as of September 30, 2024. The company implemented cost-cutting measures, realizing $3.1 million in annualized savings and reducing Q3 expenses by 54% YoY.ENDRA is focusing on securing clinical data to support a new De Novo regulatory filing with the FDA for its TAEUS liver device. The company expanded its patent portfolio to 82 issued patents globally and plans to hold periodic business update calls for shareholders going forward.

ENDRA Life Sciences reported Q3 2024 financial results and provided a business update. The company accelerated enrollment in its global multisite pilot study, with nearly 40 subjects enrolled or being scanned in the past two months. ENDRA also developed new AI-based data analysis features for its TAEUS platform and activated a system at LMU University Hospital in Germany for a post-market study.Operating expenses decreased 52% YoY to $1.5 million in Q3 2024. Net loss was $2.4 million, including a $911,000 non-cash charge related to warrants. Cash and equivalents stood at $4.7 million as of September 30, 2024. The company implemented cost-cutting measures, realizing $3.1 million in annualized savings and reducing Q3 expenses by 54% YoY.ENDRA is focusing on securing clinical data to support a new De Novo regulatory filing with the FDA for its TAEUS liver device. The company expanded its patent portfolio to 82 issued patents globally and plans to hold periodic business update calls for shareholders going forward.